Pharmagreen Biotech Stock Performance
| PHBI Stock | USD 0 0.0002 11.76% |
The company holds a Beta of 0.74, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pharmagreen Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pharmagreen Biotech is expected to be smaller as well. At this point, Pharmagreen Biotech has a negative expected return of -0.39%. Please make sure to check Pharmagreen Biotech's information ratio and the relationship between the maximum drawdown and day typical price , to decide if Pharmagreen Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pharmagreen Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental drivers remain fairly strong which may send shares a bit higher in March 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
| Begin Period Cash Flow | 25.3 K | |
| Free Cash Flow | -426.6 K |
Pharmagreen |
Pharmagreen Biotech Relative Risk vs. Return Landscape
If you would invest 0.25 in Pharmagreen Biotech on November 3, 2024 and sell it today you would lose (0.10) from holding Pharmagreen Biotech or give up 40.0% of portfolio value over 90 days. Pharmagreen Biotech is currently does not generate positive expected returns and assumes 9.8714% risk (volatility on return distribution) over the 90 days horizon. In different words, 87% of pink sheets are less volatile than Pharmagreen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pharmagreen Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmagreen Biotech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pharmagreen Biotech, and traders can use it to determine the average amount a Pharmagreen Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0399
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PHBI |
Estimated Market Risk
| 9.87 actual daily | 87 87% of assets are less volatile |
Expected Return
| -0.39 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pharmagreen Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharmagreen Biotech by adding Pharmagreen Biotech to a well-diversified portfolio.
Pharmagreen Biotech Fundamentals Growth
Pharmagreen Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pharmagreen Biotech, and Pharmagreen Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharmagreen Pink Sheet performance.
| Return On Asset | -2.3 | |||
| Current Valuation | 3.12 M | |||
| Shares Outstanding | 454.76 M | |||
| EBITDA | (828.26 K) | |||
| Cash And Equivalents | 24.26 K | |||
| Total Debt | 119.47 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (426.57 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 208.97 K | |||
About Pharmagreen Biotech Performance
By evaluating Pharmagreen Biotech's fundamental ratios, stakeholders can gain valuable insights into Pharmagreen Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharmagreen Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharmagreen Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Pharmagreen Biotech Inc., a biotech sciences solutions company, focuses on the production of starter plantlets for CBD hemp and medical cannabis industries. The company was incorporated in 2007 and is headquartered in Coquitlam, Canada. Pharmagreen Biotech is traded on OTC Exchange in the United States.Things to note about Pharmagreen Biotech performance evaluation
Checking the ongoing alerts about Pharmagreen Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pharmagreen Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharmagreen Biotech generated a negative expected return over the last 90 days | |
| Pharmagreen Biotech has high historical volatility and very poor performance | |
| Pharmagreen Biotech has some characteristics of a very speculative penny stock | |
| Pharmagreen Biotech currently holds 119.47 K in liabilities. Pharmagreen Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Pharmagreen Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Pharmagreen Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pharmagreen Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pharmagreen to invest in growth at high rates of return. When we think about Pharmagreen Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (875.48 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pharmagreen Biotech currently holds about 24.26 K in cash with (426.57 K) of positive cash flow from operations. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pharmagreen Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharmagreen Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Pharmagreen Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharmagreen Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharmagreen Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharmagreen Biotech's pink sheet. These opinions can provide insight into Pharmagreen Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharmagreen Pink Sheet analysis
When running Pharmagreen Biotech's price analysis, check to measure Pharmagreen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagreen Biotech is operating at the current time. Most of Pharmagreen Biotech's value examination focuses on studying past and present price action to predict the probability of Pharmagreen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagreen Biotech's price. Additionally, you may evaluate how the addition of Pharmagreen Biotech to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |